Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Johnson Matthey Plc    JMAT   GB00BZ4BQC70

JOHNSON MATTHEY PLC

(JMAT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Johnson Matthey : JM to manufacture regulatory starting materials for Sarepta Therapeutics

share with twitter share with LinkedIn share with facebook
09/04/2020 | 10:37am EDT

Johnson Matthey to manufacture regulatory starting materials for Sarepta Therapeutics' RNA technology-based clinical and commercial programmes.

Johnson Matthey (JM), a global leader in science that enables a cleaner and healthier world, has entered into a five-year supply agreement with Sarepta Therapeutics, Inc. to continue supplying regulatory starting materials to support Sarepta's phosphorodiamidate morpholino oligomer (PMO) and peptide phosphorodiamidate morpholino oligomer (PPMO) programmes used for the treatment of Duchenne Muscular Dystrophy.

Sarepta is the leader in precision genetic medicine for rare diseases and working to change the lives of people living with rare diseases. Johnson Matthey's Innovator Products & Solutions business that provides Custom Development and Manufacturing Services (CDMO) will produce these synthetic regulatory starting materials at their facilities in West Deptford, NJ and Devens, MA using their commercial-scale production trains.

'JM is delighted to further strengthen our relationship with Sarepta through this manufacturing agreement,' said Alex Zahiri, Vice President, Innovator Products & Solutions (CDMO) business, Johnson Matthey. 'Our collaboration with Sarepta signifies our continued commitment to existing and future PPMO and PMO programs, and Sarepta's mission of engineering precision medicine for rare, devastating diseases.'

'Sarepta's growing pipeline requires best in class manufacturing expertise in order to deliver on our commitment to patients. We are excited to expand and extend our agreement with Johnson Matthey as a manufacturing partner for our PMO and PPMO platforms,' said Bill Ciambrone, Executive Vice President, Technical Operations, Sarepta.

As leaders in the complex technologies behind a wide variety of healthcare products and services, Johnson Matthey provides its global customers with expertise in complex active pharmaceutical ingredient development and manufacture, solid form sciences, particle engineering, and catalysts. JM uses its cutting-edge science to create solutions that improve healthcare and make a real difference to the world around us.

Contact:

Tel: 54 230 4529999

Fax: 54 230 4529990

(C) 2020 Electronic News Publishing, source ENP Newswire


Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON MATTHEY PLC -1.12% 2383 Delayed Quote.-19.56%
SAREPTA THERAPEUTICS, INC. -2.34% 137.5 Delayed Quote.6.56%
share with twitter share with LinkedIn share with facebook
All news about JOHNSON MATTHEY PLC
05:20aJOHNSON MATTHEY : JM expands fuel cell component manufacturing operations into C..
PU
10/14DOW : Chinese court rules in favour of Dow and Johnson Matthey in trade secrets ..
AQ
10/13JOHNSON MATTHEY : Chinese court rules in favor of Dow and Johnson Matthey in tra..
PU
09/21JOHNSON MATTHEY : Enabling the transition to the hydrogen economy
AQ
09/21JOHNSON MATTHEY PLC : Crossing thresholds
CO
09/18JOHNSON MATTHEY : Enabling the transition to the hydrogen economy
PU
09/09KBR and Johnson Matthey sign Alliance Agreement to License innovative Ammonia..
AQ
09/09JOHNSON MATTHEY : JM and KBR sign global strategic alliance for ammonia-methanol..
AQ
09/08JOHNSON MATTHEY : JM and KBR sign global strategic alliance for ammonia-methanol..
PU
09/08JOHNSON MATTHEY : and KBR sign global strategic alliance for ammonia-methanol co..
AQ
More news
Financials
Sales 2021 3 718 M 4 854 M 4 854 M
Net income 2021 253 M 330 M 330 M
Net Debt 2021 1 034 M 1 350 M 1 350 M
P/E ratio 2021 18,3x
Yield 2021 2,38%
Capitalization 4 640 M 6 013 M 6 058 M
EV / Sales 2021 1,53x
EV / Sales 2022 1,42x
Nbr of Employees 13 632
Free-Float 95,0%
Chart JOHNSON MATTHEY PLC
Duration : Period :
Johnson Matthey Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON MATTHEY PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 2 531,32 GBX
Last Close Price 2 410,00 GBX
Spread / Highest target 45,2%
Spread / Average Target 5,03%
Spread / Lowest Target -29,5%
EPS Revisions
Managers
NameTitle
Robert James MacLeod Chief Executive Officer & Executive Director
Patrick Webster Thomas Chairman
Anna O. Manz Chief Financial Officer & Director
Paul Jonathan Coby Chief Information Officer
Maurits Van Tol Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON MATTHEY PLC-19.56%6 013
ECOLAB INC.5.19%57 936
GIVAUDAN SA28.97%39 763
SIKA AG26.48%35 932
EMS-CHEMIE HOLDING AG33.46%21 900
SYMRISE AG22.97%18 478